Hosted on MSN
This high-severity Chrome Gemini vulnerability lets malicious extensions spy on your PC
Researchers found a high-severity bug in Chrome's Gemini feature. It grants extensions the ability to spy on you or steal your data. Update now. A new vulnerability impacting Google Chrome's Gemini ...
A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how ...
Google has fixed a high-severity flaw in its implementation of Gemini AI in the Chrome browser that could have allowed attackers to escalate privileges, violate user privacy while browsing, and access ...
WebRTC skimmer exploits PolyShell flaw since March 19, hitting 56.7% stores, enabling stealth data theft bypassing CSP.
Why Two Chicks Aesthetics Is Port Jefferson’s New Boutique Injection Destination Port Jefferson, United States - March 3, 2026 / Two Chicks Aesthetics / Two Chicks Aesthetics, a boutique injection ...
Medicus Pharma Ltd ( (MDCX)) has shared an announcement. Medicus Pharma has released an interpretation of Phase 2 data for its SkinJect microneedle delivery system in basal cell carcinoma, ...
Researchers found a high-severity bug in Chrome's Gemini feature. It grants extensions the ability to spy on you or steal your data. Update now. A new vulnerability impacting Google Chrome's Gemini ...
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 ...
As the hubbub around cryptocurrencies continues to grow, so, too do the ways that more nefarious folks can exploit clueless individuals. And one coder has shown how you could be at risk when browsing ...
Hosted on MSN
Twice-yearly injectable HIV regimen treatment demonstrates strong efficacy and safety in Phase 2 trial
A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results